News | May 08, 2024
AstraZeneca completes equity investment agreement with Cellectis
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
Clinical studies are expected to start in Q2 2023.
This clearance allows the company to initiate a clinical trial for patients with an ileal pouch-anal anastomosis
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
Subscribe To Our Newsletter & Stay Updated
